News & Events about Ventyx Biosciences Inc.
Ventyx Biosciences, Inc. (NASDAQ:VTYX Get Rating) Director William Richard White sold 33,353 shares of the firms stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $35.10, for a total value of $1,170,690.30. The transaction was ...
Ventyx Biosciences, Inc. (NASDAQ:VTYX Get Rating) Director William Richard White sold 33,353 shares of the firms stock in a transaction on Monday, January 23rd. The stock was sold at an average price of $35.10, for a total value of $1,170,690.30. The transaction was disclosed in a legal filing with ...
Phase 2 clinical trials of VTX958 (TYK2 inhibitor) in plaque psoriasis, Crohns disease and psoriatic arthritis are ongoing with topline Phase 2 data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis is on track to complete enrollment by mid-...
New directors replace current directors Richard Gaster, M.D., Ph.D., Aaron Royston, M.D., and Jigar ChokseyENCINITAS, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (Ventyx), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that ...
ENCINITAS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (Ventyx), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that it...